How to cite item

Additive effects of atezolizumab and bevacizumab plus chemotherapy for patients with non-small cell lung cancer regardless of presence of EGFR mutations, ALK rearrangements, or PD-L1 expression

   
@article{TCR23555,
	author = {Takehiro Uemura and Toyoaki Hida},
	title = {Additive effects of atezolizumab and bevacizumab plus chemotherapy for patients with non-small cell lung cancer regardless of presence of EGFR mutations, ALK rearrangements, or PD-L1 expression},
	journal = {Translational Cancer Research},
	volume = {7},
	number = {Suppl 7},
	year = {2018},
	keywords = {},
	abstract = {The first-line treatment protocol for advanced non-small cell lung cancer (NSCLC) has improved with immune checkpoint inhibitor (ICI) development. The Food and Drug Administration (FDA) has approved three ICIs for second-line treatment of NSCLC (nivolumab, pembrolizumab, and atezolizumab), and randomized studies have shown superior overall survival (OS) with ICIs compared with second-line docetaxel (1-4).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/23555}
}